Compare MPLX LP (MPLX) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MPLX LP vs State Street SPDR S&P Biotech ETF — how do they compare? MPLX LP trades at $56.35 (market cap $58.11B), while State Street SPDR S&P Biotech ETF trades at $153.81 (market cap $10.11B). The key difference: MPLX LP is far larger — about 5.7× State Street SPDR S&P Biotech ETF's market cap, and MPLX LP pays a 7.51% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals.
| MPLX | XBI | |
|---|---|---|
Market Cap | $58.11B | $10.11B |
Volume | 687,483 | 12,903,266 |
Sector | Energy | Broad Market / Factor |
52-Week High | $60.51 | $169.55 |
52-Week Low | $47.80 | $104.99 |
Enterprise Value | $83.22B | — |
Dividend Yield | 7.51% | — |
Typical Hold Time | — | 38 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MPLX trades at $56.30, down 1.31% today, with a bearish technical signal and mixed earnings history including a recent Q2 2026 EPS miss. The company maintains strong profitability with a 40.45% net income margin and robust cash flow, supporting a $1.08 dividend. Analyst consensus is bullish with a $63.80 price target, though technical indicators show near-term resistance at $58.
The outlook for MPLX is positive due to its fee-based revenue model, high dividend yield, and analyst support, but risks include energy market volatility and recent earnings misses. Investors may find value in its cash flow stability, though caution is warranted given bearish technical trends and macroeconomic pressures on the energy sector.
XBI trades at $153.75, up 2.34% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts like the Merck-Moderna cancer vaccine breakthrough.
Outlook remains mixed with 100% analyst hold rating contrasting with bullish news catalysts. Key risks include high volatility, sector-specific regulatory pressures, and expense ratios higher than broader healthcare ETFs. The current technical setup near resistance requires monitoring for breakout confirmation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MPLX LP
MPLX LP is a Master Limited Partnership (MLP) formed by Marathon Petroleum Corporation (MPC). It is a diversified, growth-oriented company primarily engaged in the gathering, processing, and transportation of natural gas and natural gas liquids (NGLs), as well as the transportation, storage, and distribution of crude oil and refined petroleum products. MPLX owns and operates a network of midstream energy infrastructure assets, providing essential services to the energy industry across the United States.
Read more on MPLX →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
